Otsuka, Lundbeck Receive FDA Approval for New Alzheimer’s Medication
Rexulti to be first authorized treatment for agitation associated with dementia.
Otsuka Pharmaceutical, a global healthcare company, has received FDA approval for a new dementia drug in association with Lundbeck, a pharmaceutical organization specializing in brain diseases. As the first of its kind to be authorized, Rexulti focuses on combating agitation for those with Alzheimer’s disease.
Previously, the FDA granted Rexulti priority review, designating it a significant improvement in the effectiveness of a treatment.
“This approval is a testament to our commitment and unwavering support of patients and caregivers to lessen the symptoms of agitation associated with dementia due to Alzheimer’s disease,” said Deborah Dunsire, CEO, president, Lundbeck. “We look forward to offering this first FDA-approved treatment option to address this significant unmet need for patients.”
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Social Media's Influence on Young Women's Reproductive Decisions
February 20th 2025In this Q&A, Organon's Chief Communications Officer, Becky Edwards discusses how much social media and influencers sway decisions about birth control methods, potential consequences of these misinformed choices, and more.
